Switching From SSRI to Desvenlafaxine on Cognitive Functioning

April 17, 2019 updated by: Narcis Cardoner, MD, PhD, Corporacion Parc Tauli

Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression

Given the importance of cognitive function on depressed patients' treatment outcome and return to premorbid functioning, the effect of antidepressant drugs on cognition has become of primary concern. The aim of the present study is to assess the clinical outcome of switching from a selective serotonin reuptake inhibitor (SSRI) to desvenlafaxine on cognitive function in a Spanish sample of adults with moderate to severe major depressive disorder (MDD).

This open-label clinical study will include a total of 36 MDD outpatients receiving treatment with desvenlafaxine according to treating psychiatrist clinical judgment.

The primary efficacy endpoint will be changes from baseline to week 12 in cognitive function measured by a composite z-score comprising the Digit Symbol Substitution Test (DSST) and Rey Auditory Verbal Learning Test (RAVLT) scores. The secondary efficacy endpoints will involve depression severity, additional measures of subjective and objective cognitive function (including cold and hot cognitive function tasks), and functional status.

A matched sample of 36 healthy controls will be assessed in order to obtain reference data for all cognitive function measurements. Patients with MDD and healthy controls will be compared regarding cognitive function both at baseline and after 12 weeks.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND

Depression is a significant contributor to the global burden of disease and affects people in all communities across the world. Today, depression is estimated to affect 350 million people. The World Mental Health Survey conducted in 17 countries found that, on average, about 1 in 20 people reported having an episode of depression in the previous year. Depressive disorders often start at a young age; drastically reduce people's functioning and often are recurring. For all these reasons, depression is the leading cause of disability worldwide in terms of total years lost due to disability.

Commonly the diagnosis and treatment of major depressive disorder is based on mood symptoms. However, cognitive impairments are often present in this disorder. In this respect, the recent Diagnostic and Statistical Manual 5 (DSM-5) highlight impairment in cognitive function as a criterion in the diagnosis of a major depressive episode (MDE) (American Psychiatric Association. At clinical level, patients frequently present subjective complaints during and after resolution of an MDE. Moreover, objective deficits measured by neuropsychological tests are also reported in different cognitive domains in cold cognitive function - executive function, processing speed, attention, learning or memory- (Hammar &Ardal, 2009) or also in hot cognitive function -negative biases in perception, attention and memory, and aberrant reward/punishment processing-.

Different meta-analyses have demonstrated that these deficits may emerge from the first depressive episode with relevant intensification during each acute MDE persisting in some depressive patients even during the resolution of the acute episode. These deficits, both in an acute episode and in remission, have a relevant impact on clinical and functional outcomes, in the first case by reducing the chance to fully recover and in the second by increasing the risk of relapse. Moreover, cognitive deficits have shown to have a negative influence in functional performance in academic, social and working life (Lee et al., 2013,). In this context, recent studies have shown that a larger number of MDD episodes, a longer duration of illness and a poor response to antidepressant treatments might explain the maintenance of cognitive dysfunction, even in patients with some clinical response.

Persistent cognitive deficits in depression play a crucial role in some patients׳ ability to achieve a functional recovery. With this respect, cognitive function in depression is significantly also related to employment status. A preliminary study suggests that deficits in executive functioning have a mediating effect on the relationship between depression and impaired activities of daily living. Moreover, mood disorder patients with neuropsychological deficits tend to be less compliant with antidepressant treatment (Martinez-Aran et al., 2009) and show an increased risk for suicide. In this context, the identification and treatment of specific cognitive deficits may be a cardinal aspect in the achievement of depression recovery and, even more important, in the functional normalization of patients to their pre-morbid levels.

At present there is a growing interest on the role of antidepressant treatment in the modulation of cognitive deficits associated with depression. Despite the wide array of effective antidepressant agents, the knowledge on the impact of available drugs on cognitive function constitutes a relevant unmet need. Indeed, the number of studies focusing on this issue is relatively scarce and the outcome of cognitive symptoms is widely variable. Potential pro-cognitive effect of a particular antidepressant mostly relay on its specific mechanisms of action, anf in the last years the evidence accumulated have support that drug involving more targets such as dual (duloxetine) or multimodal (vortioxetine) antidepressants show more pro-cognitive properties than those with one major mechanism (SSRI).

However, the clinical studies putting cognitive dysfunction as the primary outcome in depression trials are scarce and further support of these initial promising findings of the effects of dual/multimodal antidepressants on cognition are required.

OBJECTIVES

This open-label clinical study will evaluate the clinical outcome of switching to desvenlafaxine on cognitive function of patients with major depressive disorder with inadequate response to selective serotonin reuptake inhibitor (SSRI)

* Primary Objective

To study differences in cognitive function in moderate to severe MDD patients with inadequate response to SSRI and healthy controls at baseline and after 12 weeks of treatment with desvenlafaxine.

* Secondary Objective

To study differences in subjective cognitive function (cognitive complains), measured by PDQ-5 at baseline and after 12 weeks of treatment with Desvenlafaxine.

To study differences in cognitive function, measured by neuropsychological tests battery (including cold and hot cognitive function) at baseline and after 12 weeks of treatment with desvenlafaxine.

To study differences in depression severity, measured HDRS-17 and CGI at baseline and after 12 weeks of treatment with desvenlafaxine.

To study changes in subjective remission and functional status measured with Remission Depression Questionnaire (RDQ) and the Short Assessement Functioning Test (FAST), respectively.

Study Type

Observational

Enrollment (Anticipated)

36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Sabadell, Spain, 08208
        • Recruiting
        • Corporacio Sanitaria Parc Tauli
        • Contact:
        • Contact:
          • Maria Serra-Blasco, PhD
          • Phone Number: +0034937240182 +0034937240182
          • Email: mserrab@tauli.cat

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 56 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients attending at the outpatient unit at the Psychiatry Department of the Hospital Universitari Parc Taulí will be consecutively recruited until the study sample (36) is reached.

Healthy controls will be seek from the same socio-demographic environment as patients (Vallès area, Spain)

Description

Inclusion Criteria:

  1. MDD Patients in whom switching to desvenlafaxine is considered by treating psychiatrist as the next treatment option.
  2. MDD diagnostic confirmation with the mini-international neuropsychiatric interview (MINI) (Sheehan et al., 1998),
  3. Age range between 18 and 60
  4. Non-response or incomplete response to a treatment with an SSRI in the current episode.
  5. Score of 18 points or higher in the Hamilton depression rating scale (HAM-D-17) (Hamilton, 1967).

Exclusion Criteria:

  1. Subjects will be excluded if they met criteria or had past history for the following disorders: posttraumatic stress disorder, obsessive-compulsive disorder, schizophrenia, psychotic, delusional, bipolar or substance abuse disorders. MINI will be used to exclude these potentially comorbid disorders.
  2. Subjects with any present or past disease involving the nervous central system
  3. A clinically significant unstable illness or clinically significant abnormal vital signs as determined by the investigator
  4. Women entering the study could not be pregnant, and had to be oral contraceptive-free.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MDD
Patients who met DSM-5 criteria for MDD attending the outpatient psychiatric service of the Hospital Universitari Parc Taulí. Patients must have a lack of response to SSRI (Maximize dose for adequate time), being the next therapeutic option the introduction of desvenlafaxine.
Drug: Desvenlafaxine
Patients included in the study will receive antidepressant treatment with desvenlafaxine. The switch from SSRI to desvenlafaxine will coincide with the baseline visit (Visit 0). The dose of desvenlafaxine will be established based on clinical judgment. As the approach will be naturalistic, the inclusion in this study will not influence the clinical choice, hence changes in the pharmacological strategy will be permitted.
Healthy Controls
Healthy participants matched by age, gender and educational level without history of psychiatric disorders and no familial history of mood disorders will be recruited

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite cognitive measure
Time Frame: Change from baseline to 12 weeks
Composite z-score (Digit Symbol Substitution Test (DSST) + Rey Auditory Verbal Learning Test (RAVLT))
Change from baseline to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Subjective cognitive function
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Perceived deficit Questionnaire short version (PDQ-5)
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Attention
Time Frame: Baseline and after 12 weeks
Attention (Digits subtest forward -WAIS-IV- + Trail Making Test-A, TMT-A)
Baseline and after 12 weeks
Processing speed
Time Frame: Baseline and after 12 weeks
Psychomotor velocity (Digit Symbol Substitution Test, DSST)
Baseline and after 12 weeks
Verbal Memory
Time Frame: Baseline and after 12 weeks

Memory cognitive domain explored with:

- Rey Auditory Verbal Learning Test (Verbal)
Baseline and after 12 weeks
Executive Functions
Time Frame: Baseline and after 12 weeks
Composite score composed by: Trail Making Test-B + Phonetic fluency & semantic fluency + Wisconsin Card Sorting Test
Baseline and after 12 weeks
Hot cognition
Time Frame: Baseline and after 12 weeks

Emotion recognition ability explored with:

- Pictures of Facial Affect (POFA)
Baseline and after 12 weeks
Intelligence quotient
Time Frame: Baseline
Measure of pre-morbid intelligence (Vocabulary (WAIS IV) + Block Design (WAIS-IV))
Baseline
Depressive symptoms
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week

The Hamilton Depression Rating Scale, 17 items (HDRS), designed to rate the severity of depression in patients.

0 - 7 = Normal 8 - 13 = Mild Depression 14-18 = Moderate Depression 19 - 22 = Severe Depression >23 = Very Severe Depression
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Anxiety symptoms
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week

The Hamilton Anxiety Rating Scale (HAM-A), to measure the severity of anxiety symptoms.

14-17 = Mild Anxiety 18-24 = Moderate Anxiety 25-30 = Severe Anxiety
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Severity and improvement of depression
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
The Clinical Global Impression (CGI)
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Self-perceived remission status
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
The Remission from Depression Questionnaire (RDQ)
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
Disability
Time Frame: Baseline and after 12 weeks
Functional disability measured with the Sheehan Disability Scale (SDS) SDS: developed to assess functional impairment in three inter-related domains; work/school, social and family life. The 3 items can also be summed into a single dimensional measure of global functional impairment that rages from 0 (unimpaired) to 30 (highly impaired).
Baseline and after 12 weeks
Functioning
Time Frame: Baseline and after 12 weeks

Functioning Assessment Short Test (FAST)

FAST: brief instrument designed to assess the main functioning problems experienced by psychiatric patients, particularly those with mood disorders. Scores > 11(out of 75)= Impairment.
Baseline and after 12 weeks
Sexual dysfunction
Time Frame: Baseline and after 12 weeks
The Arizona Sexual Experience Scale (ASEX): a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm.
Baseline and after 12 weeks
Side effect rating scale for psychotropic drugs
Time Frame: Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week
The UKU side effect rating scale: A Comprehensive Rating Scale for Psychotropic Drugs and a Cross-sectional Study of Side Effects in Neuroleptic-treated Patients.
Baseline, 2nd week, 4th week, 6th week, 8th week, 10th week, 12th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Corporacion Parc Tauli

Collaborators

Pfizer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2018

Primary Completion (Anticipated)

June 3, 2019

Study Completion (Anticipated)

June 3, 2019

Study Registration Dates

First Submitted

January 8, 2018

First Submitted That Met QC Criteria

February 7, 2018

First Posted (Actual)

February 14, 2018

Study Record Updates

Last Update Posted (Actual)

April 18, 2019

Last Update Submitted That Met QC Criteria

April 17, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2017.116

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe